CStone Pharmaceuticals
基石藥業
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT
CSTONE WILL PRESENT REGISTRATIONAL CLINICAL STUDY DATA OF SUGEMALIMAB IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER IN AN ORAL PRESENTATION AT ESMO CONGRESS 2021

CStone Pharmaceuticals (the "**Company**" or "**CStone**") is pleased to announce that that data from the GEMSTONE-301 study, a registrational Phase III study of sugemalimab for the treatment of patients with stage III non-small cell lung cancer ("**NSCLC**"), was accepted as a late-breaking abstract ("**LBA**") at the European Society for Medical Oncology ("**ESMO**") Congress 2021, and unveiled via a mini oral presentation at the ESMO Congress 2021.

Key Highlights:

- Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival ("**PFS**") in patients with stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy

- The data showed that sugemalimab demonstrated a statistically significant and clinically meaningful improvement in the Blinded Independent Central Review ("**BICR**") assessed PFS. The risk of disease progression or death was reduced by 36%, together with encouraging overall survival ("**OS**"). The risk of death was lowered by 56%. Subgroup analyses demonstrated clinical benefits regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab

- The National Medical Products Administration ("**NMPA**") of China has accepted the new drug application ("**NDA**") for sugemalimab in patients with unresectable stage III NSCLC

Summary of the Conference:

- Presentation session: Non-metastatic NSCLC and other thoracic malignancies
- Date: 23:50-23:55 (Beijing time), September 18th, 2021
- Format: Mini Oral Presentation
- Title: GEMSTONE-301: A randomized, double-blind, placebo-controlled, Phase III study of sugemalimab in patients with unresectable stage III NSCLC who had not progressed after concurrent or sequential chemoradiotherapy ("**CRT**")
- Presentation number: LBA 43
- Principal Investigator & presenter: Professor Yi-Long Wu, Guangdong Provincial People's Hospital

The GEMSTONE-301 study is designed to evaluate the efficacy and safety of sugemalimab as a consolidation therapy in patients with unresectable stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy. The GEMSTONE-301 study has an innovative study design that enrolled patients with either concurrent or sequential chemoradiotherapy to better reflect real-world clinical practice and cover a broad NSCLC patient population. In May 2021, the GEMSTONE-301 study met its primary endpoint at the planned interim analyses reviewed by the independent Data Monitoring Committee ("**iDMC**"). The data showed that sugemalimab as a consolidation therapy brought statistically significant and clinically meaningful improvement in PFS as assessed by BICR. The detailed results of sugemalimab versus placebo as a consolidation therapy reported at the ESMO Congress 2021 are displayed as follows:

- BICR-assessed PFS was 9.0 months vs 5.8 months, stratified HR=0.64 (95% CI:0.48, 0.85), p-value=0.0026
- Clinical benefits were observed in patients who received either concurrent or sequential chemoradiotherapy prior to sugemalimab:
    - For patients who received prior concurrent chemoradiotherapy: The median PFS was 10.5 months vs 6.4 months, HR=0.66
    - For patients who received prior sequential chemoradiotherapy: The median PFS was 8.1 months vs 4.1 months, HR=0.59
- The median OS was not reached vs 24.1 months, stratified HR=0.44
- Sugemalimab had a well-tolerated safety profile; no new safety signals were observed.
    - Grade≥3 treatment-emergent adverse events ("**TEAEs**") occurred in 24.3% and 23.8% of patients in the two groups, respectively

Professor Yi-Long Wu of Guangdong Provincial People's Hospital, the Leading Principal Investigator on the GEMSTONE-301 study, said, "There is no effective therapy available for patients with stage III NSCLC without disease progression after sequential chemoradiotherapy. The data from GEMSTONE-301 showed that sugemalimab as a consolidation therapy brought statistically significant and clinically meaningful improvement in the PFS. Clinical benefits were observed in patients receiving either concurrent or sequential chemoradiotherapy prior to sugemalimab, together with a well-tolerated safety profile. With the successful data in GEMSTONE-301, sugemalimab will be well positioned to address the urgent medical needs of this patient population."

Dr. Jason Yang, Chief Medical Officer of CStone, said, "We are very glad that the GEMSTONE-301 study has been accepted for a LBA at the ESMO Congress 2021. We are so proud that these positive data have attracted extensive attention worldwide and stimulated lively discussions in the international congress. CStone is always committed to addressing unmet medical needs, and, with the GEMSTONE-301 study, we are supporting the multidisciplinary team ("**MDT**") cooperation and bolstering medical capabilities for the diagnosis and treatment of stage III lung cancer in China. Based on the positive data in patients with locally advanced (stage III) and metastatic (stage IV) NSCLC, sugemalimab has the potential to become the world's first anti-PD (L) 1 monoclonal antibody approved for the treatment of all-comer patients from both stage III and stage IV NSCLC. Meanwhile, we will continue to advance the registrational clinical study of sugemalimab in esophageal squamous cell carcinoma, gastric cancer, and relapsed/refractory extranodal natural killer/T-cell lymphoma to benefit more cancer patients."

The NMPA of China has currently accepted the NDA for sugemalimab in the treatment of patients with unresectable stage III NSCLC. The NDA for sugemalimab in patients with metastatic (stage IV) NSCLC was accepted by the NMPA of China last year and is currently under review.

CStone is working closely with Pfizer to advance the commercialization of sugemalimab in Mainland China. Outside of the Greater China, CStone will continue to work closely with EQRx on regulatory discussions on the two indications of stage III and stage IV NSCLC in multiple countries and regions.

About NSCLC

In recent years, China has had rising lung cancer incidence. According to the latest estimates on the global burden of cancer released by International Agency for Research on Cancer ("**IARC**"), in 2020, an estimated 0.82 million new lung cancer cases and 0.71 million new lung cancer deaths occurred in China. Among all Chinese cancer patients, lung cancer is the leading cause of cancer-related deaths. NSCLC is the most common type of lung cancer.

About Sugemalimab (anti-PD-L1 antibody)

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by the U.S.-based Ligand Corporation, sugemalimab is developed by the OmniRat® transgenic animal platform, which can generate fully human antibodies in one stop. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 ("**IgG4**") human antibody, which reduces the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs.

Currently, sugemalimab is being investigated in a number of ongoing clinical trials, including one Phase II registration study for lymphoma (CS1001-201) and four Phase III registrational studies in stage III NSCLC, stage IV NSCLC, gastric cancer, and esophageal cancer, respectively.

CS1001-201 is a single-arm, multicenter, Phase II pivotal study designed to evaluate the efficacy and safety of sugemalimab as monotherapy for the treatment of adult patients with relapsed or refractory extranodal natural killer/T-cell lymphoma ("**R/R ENKTL**"). Based on the encouraging preliminary efficacy results, sugemalimab was granted Orphan Drug Designation for the treatment of T-cell lymphoma and Breakthrough Therapy Designation for the treatment of R/R ENKTL by the U.S. Food and Drug Administration. It has also been granted Breakthrough Therapy Designation by the NMPA of China. The proposed indication is R/R ENKTL.

CStone formed a strategic collaboration agreement with Pfizer that includes the development and commercialization of sugemalimab in mainland China, and a framework to bring additional oncology assets to the Greater China market. CStone subsequently formed a strategic collaboration agreement with EQRx, under which EQRx licensed the exclusive rights to two key late-stage immuno-oncology assets, sugemalimab and CS1003 (anti-PD-1 antibody), for development and commercialization outside of Greater China.

About GEMSTONE-301 study

GEMSTONE-301 study (clinicaltrials.gov registration number: NCT03728556; drug clinical trial registration number: CTR20181429) is a multicenter, randomized, double-blind Phase III clinical trial, designed to evaluate the efficacy and safety of sugemalimab as consolidation therapy in patients with unresectable stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy. The trial's primary endpoint was PFS as assessed by BICR according to RECIST v1.1; the secondary endpoints included OS, PFS as assessed by investigators and safety profile.

In May 2021, the GEMSTONE-301 study met its primary endpoint at a pre-planned interim analysis reviewed by the iDMC. The findings showed that sugemalimab brought statistically significant and clinically meaningful improvement in the BICR assessed PFS. Investigator-assessed PFS showed consistent results as those of the primary endpoint. Sugemalimab was well-tolerated with no new safety signals. Subgroup analyses demonstrated that sugemalimab was associated with clinical benefit regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.

In September 2021, the NMPA of China accepted the NDA for sugemalimab as a consolidation therapy in patients with unresectable stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy.

About GEMSTONE-302 study

GEMSTONE-302 (clinicaltrials.gov registration number: NCT03789604; drug clinical trial registration number: CTR20181452) is a randomized, double-blind Phase III study, designed to evaluate the efficacy and safety of anti-PD-L1 monoclonal antibody sugemalimab combined with chemotherapy as the first-line treatment in naïve patients with stage IV NSCLC vs. placebo combined with chemotherapy. The primary endpoint of the study was investigator-assessed PFS. Secondary endpoints included OS, BICR-assessed PFS and safety.

In August 2020, the GEMSTONE-302 study met its primary endpoint of significantly prolonging PFS and reducing the risk of disease progression or death by 50% with sugemalimab combined with chemotherapy compared to placebo combined with chemotherapy, as assessed by iDMC at the planned interim analysis. Specific study data were presented in a Proffered Paper Oral Presentation (Late-Breaking Abstract) at the ESMO Asia 2020.

In November 2020, the NMPA of China accepted the NDA for sugemalimab combined with chemotherapy for the first-line treatment of advanced squamous and non-squamous NSCLC patients.

In July 2021, the final analysis of PFS from the GEMSTONE-302 study showed that sugemalimab in combination with chemotherapy demonstrated further improvement in PFS and the risk of disease progression or death was reduced by 52%, together with a trend of OS benefits. The two-year survival rate was 47.1%. Data were presented in a Mini Oral Presentation (LBA) at the IASLC 2021 WCLC.

About CStone

CStone is a biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in Mainland China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The Company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in Mainland China and one in Taiwan, China. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com.

By Order of the Board
CStone Pharmaceuticals
Dr. Frank Ningjun Jiang
Chairman

Suzhou, the People's Republic of China, September 17, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and executive director, Dr. Wei Li, Mr. Qun Zhao, Mr. Yanling Cao, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.